Randomized crossover antiemetic study in cisplatin-treated patients View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1986-05

AUTHORS

Sergio Frustaci, Enore Grattoni, Salvatore Tumolo, Diana Crivellari, Franco Figoli, Enzo Galligioni, Andrea Veronesi, Umberto Tirelli, Eligio Grigoletto

ABSTRACT

This prospective, randomized, nonblind study comparing the antiemetic effectiveness of high-dose IV metoclopramide and high-dose IV dexamethasone was performed in 78 advanced cancer patients. Chemotherapeutic treatment consisted in cisplatin at a high-dose (120 mg/m2) (HD-CDDP) and at a low-dose (LD-CDDP), either alone (60 mg/m2) or in combination with other chemotherapeutic agents (50 mg/m2). The evaluation of the effectiveness of antiemetic therapy was based on three parameters: prevention of vomiting ("major protection"), number of emetic episodes, and subjective preference. Out of 78 study patients, 67 were evaluable. Overall, metoclopramide proved to be statistically superior to dexamethasone in preventing vomiting (P less than 0.005), in reducing the median/mean number of emetic episodes (P less than 0.001/0.001), and in subjective preference (P less than 0.01). The results divided between HD-CDDP and LD-CDDP groups were also in favor of metoclopramide for reduction of the median/mean number of emetic episodes (P less than 0.001/0.001 for the HD-CDDP group and P less than 0.001/0.005 for the LD-CDDP group) and in subjective preference (P less than 0.001 and P less than 0.001 for the HD- and LD-CDDP groups, respectively). No statistical differences were noted when LD-CDDP was used in monochemotherapy, whereas when LD-CDDP was used in combination chemotherapy, statistical differences in favor of metoclopramide were noted again for the median/mean number of emetic episodes (P less than 0.01/0.05) and for subjective preference (P less than 0.01), even though the effectiveness of both antiemetic agents was greatly reduced. The evaluation of previously untreated patients reflected the overall results: for the HD-CDDP group all three parameters demonstrated statistical significance in favor of metoclopramide; for the LD-CDDP group, of all three parameters, prevention of vomiting (major protection) was the only one for which there was no significant difference. Mild sedation was the only side effect of metoclopramide. No extrapyramidal reactions were noted during this trial, but concomitant orphenadrine treatment was given. Dexamethasone was always well tolerated. In conclusion, high-dose IV metoclopramide demonstrated its superiority over high-dose IV dexamethasone in all subsets of our population except the LD-CDDP monochemotherapy group, in which the two antiemetics were found to be equivalent in effect. More... »

PAGES

75-79

References to SciGraph publications

  • 1981-12. High-dose dexamethasone for prevention of cis-platin-induced vomiting in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/bf00299870

    DOI

    http://dx.doi.org/10.1007/bf00299870

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1002510487

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/3698180


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adult", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antineoplastic Combined Chemotherapy Protocols", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cisplatin", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Dexamethasone", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Infusions, Parenteral", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Metoclopramide", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Middle Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Nausea", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Neoplasms", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Random Allocation", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Centro di Riferimento Oncologico", 
              "id": "https://www.grid.ac/institutes/grid.418321.d", 
              "name": [
                "Division of Medical Oncology, Centro di Riferimento Oncologico, I-33081, Aviano, Italy", 
                "Division of Radiotherapy, Centro di Riferimento Oncologico, I-33081, Aviano, Italy"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Frustaci", 
            "givenName": "Sergio", 
            "id": "sg:person.0652421767.09", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0652421767.09"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Centro di Riferimento Oncologico", 
              "id": "https://www.grid.ac/institutes/grid.418321.d", 
              "name": [
                "Biomedical Research Service, Centro di Riferimento Oncologico, I-33081, Aviano, Italy", 
                "Division of Radiotherapy, Centro di Riferimento Oncologico, I-33081, Aviano, Italy"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Grattoni", 
            "givenName": "Enore", 
            "id": "sg:person.01172634311.28", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01172634311.28"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Centro di Riferimento Oncologico", 
              "id": "https://www.grid.ac/institutes/grid.418321.d", 
              "name": [
                "Division of Medical Oncology, Centro di Riferimento Oncologico, I-33081, Aviano, Italy", 
                "Division of Radiotherapy, Centro di Riferimento Oncologico, I-33081, Aviano, Italy"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Tumolo", 
            "givenName": "Salvatore", 
            "id": "sg:person.01154233121.81", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01154233121.81"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Centro di Riferimento Oncologico", 
              "id": "https://www.grid.ac/institutes/grid.418321.d", 
              "name": [
                "Division of Medical Oncology, Centro di Riferimento Oncologico, I-33081, Aviano, Italy", 
                "Division of Radiotherapy, Centro di Riferimento Oncologico, I-33081, Aviano, Italy"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Crivellari", 
            "givenName": "Diana", 
            "id": "sg:person.01301341745.03", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301341745.03"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Centro di Riferimento Oncologico", 
              "id": "https://www.grid.ac/institutes/grid.418321.d", 
              "name": [
                "Division of Medical Oncology, Centro di Riferimento Oncologico, I-33081, Aviano, Italy", 
                "Division of Radiotherapy, Centro di Riferimento Oncologico, I-33081, Aviano, Italy"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Figoli", 
            "givenName": "Franco", 
            "id": "sg:person.01306315563.97", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01306315563.97"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Centro di Riferimento Oncologico", 
              "id": "https://www.grid.ac/institutes/grid.418321.d", 
              "name": [
                "Division of Medical Oncology, Centro di Riferimento Oncologico, I-33081, Aviano, Italy", 
                "Division of Radiotherapy, Centro di Riferimento Oncologico, I-33081, Aviano, Italy"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Galligioni", 
            "givenName": "Enzo", 
            "id": "sg:person.01220107046.14", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01220107046.14"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Centro di Riferimento Oncologico", 
              "id": "https://www.grid.ac/institutes/grid.418321.d", 
              "name": [
                "Division of Medical Oncology, Centro di Riferimento Oncologico, I-33081, Aviano, Italy", 
                "Division of Radiotherapy, Centro di Riferimento Oncologico, I-33081, Aviano, Italy"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Veronesi", 
            "givenName": "Andrea", 
            "id": "sg:person.01106117721.12", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01106117721.12"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Centro di Riferimento Oncologico", 
              "id": "https://www.grid.ac/institutes/grid.418321.d", 
              "name": [
                "Division of Medical Oncology, Centro di Riferimento Oncologico, I-33081, Aviano, Italy", 
                "Division of Radiotherapy, Centro di Riferimento Oncologico, I-33081, Aviano, Italy"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Tirelli", 
            "givenName": "Umberto", 
            "id": "sg:person.01244630611.29", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01244630611.29"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Centro di Riferimento Oncologico", 
              "id": "https://www.grid.ac/institutes/grid.418321.d", 
              "name": [
                "Division of Medical Oncology, Centro di Riferimento Oncologico, I-33081, Aviano, Italy", 
                "Division of Radiotherapy, Centro di Riferimento Oncologico, I-33081, Aviano, Italy"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Grigoletto", 
            "givenName": "Eligio", 
            "id": "sg:person.0652333201.37", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0652333201.37"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "https://doi.org/10.1001/jama.1981.03310290055028", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1025205423"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0090-8258(80)90027-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028689789"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/s0305-7372(79)80057-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1034123492"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00258206", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1038141122", 
              "https://doi.org/10.1007/bf00258206"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00258206", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1038141122", 
              "https://doi.org/10.1007/bf00258206"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1056/nejm198110153051601", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1043397189"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1056/nejm198102193040815", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1046312240"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1056/nejm197906073002302", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1050524094"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1056/nejm197510162931603", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052681335"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.7326/0003-4819-95-3-352", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1073738932"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1080006769", 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1081644767", 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1081645942", 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1082179293", 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1082210864", 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "1986-05", 
        "datePublishedReg": "1986-05-01", 
        "description": "This prospective, randomized, nonblind study comparing the antiemetic effectiveness of high-dose IV metoclopramide and high-dose IV dexamethasone was performed in 78 advanced cancer patients. Chemotherapeutic treatment consisted in cisplatin at a high-dose (120 mg/m2) (HD-CDDP) and at a low-dose (LD-CDDP), either alone (60 mg/m2) or in combination with other chemotherapeutic agents (50 mg/m2). The evaluation of the effectiveness of antiemetic therapy was based on three parameters: prevention of vomiting (\"major protection\"), number of emetic episodes, and subjective preference. Out of 78 study patients, 67 were evaluable. Overall, metoclopramide proved to be statistically superior to dexamethasone in preventing vomiting (P less than 0.005), in reducing the median/mean number of emetic episodes (P less than 0.001/0.001), and in subjective preference (P less than 0.01). The results divided between HD-CDDP and LD-CDDP groups were also in favor of metoclopramide for reduction of the median/mean number of emetic episodes (P less than 0.001/0.001 for the HD-CDDP group and P less than 0.001/0.005 for the LD-CDDP group) and in subjective preference (P less than 0.001 and P less than 0.001 for the HD- and LD-CDDP groups, respectively). No statistical differences were noted when LD-CDDP was used in monochemotherapy, whereas when LD-CDDP was used in combination chemotherapy, statistical differences in favor of metoclopramide were noted again for the median/mean number of emetic episodes (P less than 0.01/0.05) and for subjective preference (P less than 0.01), even though the effectiveness of both antiemetic agents was greatly reduced. The evaluation of previously untreated patients reflected the overall results: for the HD-CDDP group all three parameters demonstrated statistical significance in favor of metoclopramide; for the LD-CDDP group, of all three parameters, prevention of vomiting (major protection) was the only one for which there was no significant difference. Mild sedation was the only side effect of metoclopramide. No extrapyramidal reactions were noted during this trial, but concomitant orphenadrine treatment was given. Dexamethasone was always well tolerated. In conclusion, high-dose IV metoclopramide demonstrated its superiority over high-dose IV dexamethasone in all subsets of our population except the LD-CDDP monochemotherapy group, in which the two antiemetics were found to be equivalent in effect.", 
        "genre": "research_article", 
        "id": "sg:pub.10.1007/bf00299870", 
        "inLanguage": [
          "en"
        ], 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1088364", 
            "issn": [
              "0344-5704", 
              "1432-0843"
            ], 
            "name": "Cancer Chemotherapy and Pharmacology", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "17"
          }
        ], 
        "name": "Randomized crossover antiemetic study in cisplatin-treated patients", 
        "pagination": "75-79", 
        "productId": [
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/bf00299870"
            ]
          }, 
          {
            "name": "readcube_id", 
            "type": "PropertyValue", 
            "value": [
              "0bf3bd78c1a0f9a94457a637182049b598c04453322c3202006c0de72c9450bd"
            ]
          }, 
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1002510487"
            ]
          }, 
          {
            "name": "nlm_unique_id", 
            "type": "PropertyValue", 
            "value": [
              "7806519"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "3698180"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/bf00299870", 
          "https://app.dimensions.ai/details/publication/pub.1002510487"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2019-04-15T08:49", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000374_0000000374/records_119724_00000000.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "http://link.springer.com/10.1007/BF00299870"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf00299870'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf00299870'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf00299870'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf00299870'


     

    This table displays all metadata directly associated to this object as RDF triples.

    221 TRIPLES      21 PREDICATES      57 URIs      35 LITERALS      23 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/bf00299870 schema:about N0184d485a9814eefaf2a80a0591bac9b
    2 N0d6a89018cc24c1c8a7812df9ad5cd79
    3 N1df5ba95995b4c68b2e2693893ceea05
    4 N1e76e419d9824172b316bcc2c1f83193
    5 N27f9f5ac3a4243499ca43ae3a6e0602e
    6 N2bdd5c216db84d70a830950ea7af2d07
    7 N3f194476b38948a9b97003fe31cafcd5
    8 N8e891cdfc576410b86e369f5907b84ff
    9 N9bd7552f16694a1493428de493605c4c
    10 Nc19ed90c6723467ca0eafa31182c63a8
    11 Ncade17dd41744197a2564581d60157f1
    12 Nde25a38c6ee34ce1bfe58ee749d77f94
    13 Ne587187996804ec0b62206473d99441b
    14 Nfa65b6f833ac4b0db83183e436070f23
    15 anzsrc-for:11
    16 anzsrc-for:1112
    17 schema:author Nc17618fca83f4ed89b80cabbf604a4b1
    18 schema:citation sg:pub.10.1007/bf00258206
    19 https://app.dimensions.ai/details/publication/pub.1080006769
    20 https://app.dimensions.ai/details/publication/pub.1081644767
    21 https://app.dimensions.ai/details/publication/pub.1081645942
    22 https://app.dimensions.ai/details/publication/pub.1082179293
    23 https://app.dimensions.ai/details/publication/pub.1082210864
    24 https://doi.org/10.1001/jama.1981.03310290055028
    25 https://doi.org/10.1016/0090-8258(80)90027-x
    26 https://doi.org/10.1016/s0305-7372(79)80057-2
    27 https://doi.org/10.1056/nejm197510162931603
    28 https://doi.org/10.1056/nejm197906073002302
    29 https://doi.org/10.1056/nejm198102193040815
    30 https://doi.org/10.1056/nejm198110153051601
    31 https://doi.org/10.7326/0003-4819-95-3-352
    32 schema:datePublished 1986-05
    33 schema:datePublishedReg 1986-05-01
    34 schema:description This prospective, randomized, nonblind study comparing the antiemetic effectiveness of high-dose IV metoclopramide and high-dose IV dexamethasone was performed in 78 advanced cancer patients. Chemotherapeutic treatment consisted in cisplatin at a high-dose (120 mg/m2) (HD-CDDP) and at a low-dose (LD-CDDP), either alone (60 mg/m2) or in combination with other chemotherapeutic agents (50 mg/m2). The evaluation of the effectiveness of antiemetic therapy was based on three parameters: prevention of vomiting ("major protection"), number of emetic episodes, and subjective preference. Out of 78 study patients, 67 were evaluable. Overall, metoclopramide proved to be statistically superior to dexamethasone in preventing vomiting (P less than 0.005), in reducing the median/mean number of emetic episodes (P less than 0.001/0.001), and in subjective preference (P less than 0.01). The results divided between HD-CDDP and LD-CDDP groups were also in favor of metoclopramide for reduction of the median/mean number of emetic episodes (P less than 0.001/0.001 for the HD-CDDP group and P less than 0.001/0.005 for the LD-CDDP group) and in subjective preference (P less than 0.001 and P less than 0.001 for the HD- and LD-CDDP groups, respectively). No statistical differences were noted when LD-CDDP was used in monochemotherapy, whereas when LD-CDDP was used in combination chemotherapy, statistical differences in favor of metoclopramide were noted again for the median/mean number of emetic episodes (P less than 0.01/0.05) and for subjective preference (P less than 0.01), even though the effectiveness of both antiemetic agents was greatly reduced. The evaluation of previously untreated patients reflected the overall results: for the HD-CDDP group all three parameters demonstrated statistical significance in favor of metoclopramide; for the LD-CDDP group, of all three parameters, prevention of vomiting (major protection) was the only one for which there was no significant difference. Mild sedation was the only side effect of metoclopramide. No extrapyramidal reactions were noted during this trial, but concomitant orphenadrine treatment was given. Dexamethasone was always well tolerated. In conclusion, high-dose IV metoclopramide demonstrated its superiority over high-dose IV dexamethasone in all subsets of our population except the LD-CDDP monochemotherapy group, in which the two antiemetics were found to be equivalent in effect.
    35 schema:genre research_article
    36 schema:inLanguage en
    37 schema:isAccessibleForFree false
    38 schema:isPartOf Nf3842fb849424a9b9a5d8a6d845f84bb
    39 Nf5d30671d4224a46bb0d9e1720a86861
    40 sg:journal.1088364
    41 schema:name Randomized crossover antiemetic study in cisplatin-treated patients
    42 schema:pagination 75-79
    43 schema:productId N74db6a8084d24192b4a31affcc74a568
    44 N755b5cbabb2444d999fd0d63988f9f20
    45 N77ec19b9c03648248ed92c166f616a8d
    46 N931cddb31d5e4420b72ce56037362aa3
    47 Nda2a25c9017a4a5d86b10df6309df492
    48 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002510487
    49 https://doi.org/10.1007/bf00299870
    50 schema:sdDatePublished 2019-04-15T08:49
    51 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    52 schema:sdPublisher N5a98a8a1584a4282843be28cb80a526a
    53 schema:url http://link.springer.com/10.1007/BF00299870
    54 sgo:license sg:explorer/license/
    55 sgo:sdDataset articles
    56 rdf:type schema:ScholarlyArticle
    57 N0184d485a9814eefaf2a80a0591bac9b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    58 schema:name Adult
    59 rdf:type schema:DefinedTerm
    60 N0d6a89018cc24c1c8a7812df9ad5cd79 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    61 schema:name Random Allocation
    62 rdf:type schema:DefinedTerm
    63 N1df5ba95995b4c68b2e2693893ceea05 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    64 schema:name Middle Aged
    65 rdf:type schema:DefinedTerm
    66 N1e76e419d9824172b316bcc2c1f83193 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    67 schema:name Nausea
    68 rdf:type schema:DefinedTerm
    69 N27f9f5ac3a4243499ca43ae3a6e0602e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    70 schema:name Aged
    71 rdf:type schema:DefinedTerm
    72 N2bdd5c216db84d70a830950ea7af2d07 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    73 schema:name Male
    74 rdf:type schema:DefinedTerm
    75 N3c7d9912f0de4d549f3ac068ba85e7b9 rdf:first sg:person.01306315563.97
    76 rdf:rest N695719c0169745cf9a937e4582ddcef1
    77 N3f194476b38948a9b97003fe31cafcd5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    78 schema:name Dexamethasone
    79 rdf:type schema:DefinedTerm
    80 N4b0a357c93914f92957c6c9f3825ad4d rdf:first sg:person.0652333201.37
    81 rdf:rest rdf:nil
    82 N5a98a8a1584a4282843be28cb80a526a schema:name Springer Nature - SN SciGraph project
    83 rdf:type schema:Organization
    84 N5daf485ef4ef492e8be95003141a42c7 rdf:first sg:person.01172634311.28
    85 rdf:rest Nb20f77cca65c4b229ee06d59ed3f28f1
    86 N695719c0169745cf9a937e4582ddcef1 rdf:first sg:person.01220107046.14
    87 rdf:rest Nd58063062f1f431e9a4ec257381492ee
    88 N74db6a8084d24192b4a31affcc74a568 schema:name readcube_id
    89 schema:value 0bf3bd78c1a0f9a94457a637182049b598c04453322c3202006c0de72c9450bd
    90 rdf:type schema:PropertyValue
    91 N755b5cbabb2444d999fd0d63988f9f20 schema:name dimensions_id
    92 schema:value pub.1002510487
    93 rdf:type schema:PropertyValue
    94 N77ec19b9c03648248ed92c166f616a8d schema:name nlm_unique_id
    95 schema:value 7806519
    96 rdf:type schema:PropertyValue
    97 N836895d62afa4ce2909425fdc27f4721 rdf:first sg:person.01301341745.03
    98 rdf:rest N3c7d9912f0de4d549f3ac068ba85e7b9
    99 N8e891cdfc576410b86e369f5907b84ff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    100 schema:name Female
    101 rdf:type schema:DefinedTerm
    102 N931cddb31d5e4420b72ce56037362aa3 schema:name doi
    103 schema:value 10.1007/bf00299870
    104 rdf:type schema:PropertyValue
    105 N9bd7552f16694a1493428de493605c4c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    106 schema:name Infusions, Parenteral
    107 rdf:type schema:DefinedTerm
    108 Nb20f77cca65c4b229ee06d59ed3f28f1 rdf:first sg:person.01154233121.81
    109 rdf:rest N836895d62afa4ce2909425fdc27f4721
    110 Nc17618fca83f4ed89b80cabbf604a4b1 rdf:first sg:person.0652421767.09
    111 rdf:rest N5daf485ef4ef492e8be95003141a42c7
    112 Nc19ed90c6723467ca0eafa31182c63a8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    113 schema:name Antineoplastic Combined Chemotherapy Protocols
    114 rdf:type schema:DefinedTerm
    115 Ncade17dd41744197a2564581d60157f1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    116 schema:name Humans
    117 rdf:type schema:DefinedTerm
    118 Nd58063062f1f431e9a4ec257381492ee rdf:first sg:person.01106117721.12
    119 rdf:rest Nf7281d5dd5304ad8afba8a00e6cb380b
    120 Nda2a25c9017a4a5d86b10df6309df492 schema:name pubmed_id
    121 schema:value 3698180
    122 rdf:type schema:PropertyValue
    123 Nde25a38c6ee34ce1bfe58ee749d77f94 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    124 schema:name Cisplatin
    125 rdf:type schema:DefinedTerm
    126 Ne587187996804ec0b62206473d99441b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    127 schema:name Neoplasms
    128 rdf:type schema:DefinedTerm
    129 Nf3842fb849424a9b9a5d8a6d845f84bb schema:volumeNumber 17
    130 rdf:type schema:PublicationVolume
    131 Nf5d30671d4224a46bb0d9e1720a86861 schema:issueNumber 1
    132 rdf:type schema:PublicationIssue
    133 Nf7281d5dd5304ad8afba8a00e6cb380b rdf:first sg:person.01244630611.29
    134 rdf:rest N4b0a357c93914f92957c6c9f3825ad4d
    135 Nfa65b6f833ac4b0db83183e436070f23 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    136 schema:name Metoclopramide
    137 rdf:type schema:DefinedTerm
    138 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    139 schema:name Medical and Health Sciences
    140 rdf:type schema:DefinedTerm
    141 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    142 schema:name Oncology and Carcinogenesis
    143 rdf:type schema:DefinedTerm
    144 sg:journal.1088364 schema:issn 0344-5704
    145 1432-0843
    146 schema:name Cancer Chemotherapy and Pharmacology
    147 rdf:type schema:Periodical
    148 sg:person.01106117721.12 schema:affiliation https://www.grid.ac/institutes/grid.418321.d
    149 schema:familyName Veronesi
    150 schema:givenName Andrea
    151 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01106117721.12
    152 rdf:type schema:Person
    153 sg:person.01154233121.81 schema:affiliation https://www.grid.ac/institutes/grid.418321.d
    154 schema:familyName Tumolo
    155 schema:givenName Salvatore
    156 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01154233121.81
    157 rdf:type schema:Person
    158 sg:person.01172634311.28 schema:affiliation https://www.grid.ac/institutes/grid.418321.d
    159 schema:familyName Grattoni
    160 schema:givenName Enore
    161 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01172634311.28
    162 rdf:type schema:Person
    163 sg:person.01220107046.14 schema:affiliation https://www.grid.ac/institutes/grid.418321.d
    164 schema:familyName Galligioni
    165 schema:givenName Enzo
    166 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01220107046.14
    167 rdf:type schema:Person
    168 sg:person.01244630611.29 schema:affiliation https://www.grid.ac/institutes/grid.418321.d
    169 schema:familyName Tirelli
    170 schema:givenName Umberto
    171 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01244630611.29
    172 rdf:type schema:Person
    173 sg:person.01301341745.03 schema:affiliation https://www.grid.ac/institutes/grid.418321.d
    174 schema:familyName Crivellari
    175 schema:givenName Diana
    176 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301341745.03
    177 rdf:type schema:Person
    178 sg:person.01306315563.97 schema:affiliation https://www.grid.ac/institutes/grid.418321.d
    179 schema:familyName Figoli
    180 schema:givenName Franco
    181 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01306315563.97
    182 rdf:type schema:Person
    183 sg:person.0652333201.37 schema:affiliation https://www.grid.ac/institutes/grid.418321.d
    184 schema:familyName Grigoletto
    185 schema:givenName Eligio
    186 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0652333201.37
    187 rdf:type schema:Person
    188 sg:person.0652421767.09 schema:affiliation https://www.grid.ac/institutes/grid.418321.d
    189 schema:familyName Frustaci
    190 schema:givenName Sergio
    191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0652421767.09
    192 rdf:type schema:Person
    193 sg:pub.10.1007/bf00258206 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038141122
    194 https://doi.org/10.1007/bf00258206
    195 rdf:type schema:CreativeWork
    196 https://app.dimensions.ai/details/publication/pub.1080006769 schema:CreativeWork
    197 https://app.dimensions.ai/details/publication/pub.1081644767 schema:CreativeWork
    198 https://app.dimensions.ai/details/publication/pub.1081645942 schema:CreativeWork
    199 https://app.dimensions.ai/details/publication/pub.1082179293 schema:CreativeWork
    200 https://app.dimensions.ai/details/publication/pub.1082210864 schema:CreativeWork
    201 https://doi.org/10.1001/jama.1981.03310290055028 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025205423
    202 rdf:type schema:CreativeWork
    203 https://doi.org/10.1016/0090-8258(80)90027-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1028689789
    204 rdf:type schema:CreativeWork
    205 https://doi.org/10.1016/s0305-7372(79)80057-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034123492
    206 rdf:type schema:CreativeWork
    207 https://doi.org/10.1056/nejm197510162931603 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052681335
    208 rdf:type schema:CreativeWork
    209 https://doi.org/10.1056/nejm197906073002302 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050524094
    210 rdf:type schema:CreativeWork
    211 https://doi.org/10.1056/nejm198102193040815 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046312240
    212 rdf:type schema:CreativeWork
    213 https://doi.org/10.1056/nejm198110153051601 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043397189
    214 rdf:type schema:CreativeWork
    215 https://doi.org/10.7326/0003-4819-95-3-352 schema:sameAs https://app.dimensions.ai/details/publication/pub.1073738932
    216 rdf:type schema:CreativeWork
    217 https://www.grid.ac/institutes/grid.418321.d schema:alternateName Centro di Riferimento Oncologico
    218 schema:name Biomedical Research Service, Centro di Riferimento Oncologico, I-33081, Aviano, Italy
    219 Division of Medical Oncology, Centro di Riferimento Oncologico, I-33081, Aviano, Italy
    220 Division of Radiotherapy, Centro di Riferimento Oncologico, I-33081, Aviano, Italy
    221 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...